Rhumbline Advisers Prothena Corp Public LTD CO Transaction History

Rhumbline Advisers

  • $109 Billion
  • Q3 2024

A detailed history of Rhumbline Advisers transactions in Prothena Corp Public LTD CO stock. As of the latest transaction made, Rhumbline Advisers holds 65,940 shares of PRTA stock, worth $1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
65,940
Previous 69,756 5.47%
Holding current value
$1 Million
Previous $1.44 Million 23.35%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024
SELL
$16.73 - $24.79 $63,841 - $94,598
-3,816 Reduced 5.47%
65,940 $1.1 Million
Q2 2024

Aug 01, 2024
BUY
$19.54 - $26.15 $122,242 - $163,594
6,256 Added 9.85%
69,756 $1.44 Million
Q1 2024

May 09, 2024
BUY
$24.75 - $40.66 $39,105 - $64,242
1,580 Added 2.55%
63,500 $1.57 Million
Q4 2023

Feb 08, 2024
SELL
$32.31 - $52.32 $17,156 - $27,781
-531 Reduced 0.85%
61,920 $2.25 Million
Q3 2023

Nov 09, 2023
BUY
$47.3 - $70.6 $78,565 - $117,266
1,661 Added 2.73%
62,451 $3.01 Million
Q2 2023

Aug 08, 2023
BUY
$48.26 - $78.59 $238,693 - $388,706
4,946 Added 8.86%
60,790 $4.15 Million
Q1 2023

May 11, 2023
BUY
$46.97 - $58.27 $287,738 - $356,962
6,126 Added 12.32%
55,844 $2.71 Million
Q4 2022

Feb 14, 2023
BUY
$52.05 - $65.0 $147,145 - $183,755
2,827 Added 6.03%
49,718 $3 Million
Q3 2022

Nov 10, 2022
BUY
$25.16 - $60.63 $90,223 - $217,419
3,586 Added 8.28%
46,891 $2.84 Million
Q2 2022

Aug 11, 2022
BUY
$22.73 - $39.98 $22,548 - $39,660
992 Added 2.34%
43,305 $1.18 Million
Q1 2022

May 12, 2022
SELL
$30.27 - $49.22 $63,869 - $103,854
-2,110 Reduced 4.75%
42,313 $1.55 Million
Q4 2021

Feb 10, 2022
BUY
$42.11 - $73.26 $378 - $659
9 Added 0.02%
44,423 $2.19 Million
Q3 2021

Nov 12, 2021
BUY
$48.2 - $78.89 $95,195 - $155,807
1,975 Added 4.65%
44,414 $3.16 Million
Q2 2021

Aug 05, 2021
SELL
$21.63 - $57.65 $358,755 - $956,182
-16,586 Reduced 28.1%
42,439 $2.18 Million
Q1 2021

May 06, 2021
SELL
$11.0 - $28.24 $81,070 - $208,128
-7,370 Reduced 11.1%
59,025 $1.48 Million
Q4 2020

Feb 10, 2021
BUY
$10.12 - $13.94 $51,510 - $70,954
5,090 Added 8.3%
66,395 $797,000
Q3 2020

Nov 12, 2020
SELL
$9.93 - $13.47 $69,966 - $94,909
-7,046 Reduced 10.31%
61,305 $612,000
Q2 2020

Aug 13, 2020
SELL
$9.56 - $12.51 $100,064 - $130,942
-10,467 Reduced 13.28%
68,351 $715,000
Q1 2020

May 06, 2020
BUY
$7.54 - $15.77 $84,787 - $177,333
11,245 Added 16.64%
78,818 $843,000
Q4 2019

Feb 05, 2020
BUY
$7.48 - $17.01 $16,553 - $37,643
2,213 Added 3.39%
67,573 $1.07 Million
Q3 2019

Oct 23, 2019
SELL
$6.89 - $10.45 $29,778 - $45,164
-4,322 Reduced 6.2%
65,360 $512,000
Q2 2019

Aug 14, 2019
BUY
$8.85 - $12.49 $51,135 - $72,167
5,778 Added 9.04%
69,682 $737,000
Q1 2019

May 01, 2019
BUY
$10.32 - $14.49 $66,956 - $94,011
6,488 Added 11.3%
63,904 $775,000
Q4 2018

Jan 31, 2019
BUY
$8.73 - $13.74 $153,377 - $241,398
17,569 Added 44.09%
57,416 $591,000
Q3 2018

Nov 07, 2018
BUY
$12.7 - $15.79 $1,905 - $2,368
150 Added 0.38%
39,847 $521,000
Q2 2018

Aug 06, 2018
BUY
$10.99 - $44.21 $36,365 - $146,290
3,309 Added 9.09%
39,697 $579,000
Q1 2018

May 02, 2018
SELL
$27.95 - $45.04 $59,393 - $95,710
-2,125 Reduced 5.52%
36,388 $1.34 Million
Q4 2017

Feb 09, 2018
SELL
$35.44 - $63.76 $296,242 - $532,969
-8,359 Reduced 17.83%
38,513 $1.44 Million
Q3 2017

Nov 06, 2017
BUY
$53.83 - $67.75 $2.52 Million - $3.18 Million
46,872
46,872 $3.04 Million

Others Institutions Holding PRTA

# of Institutions
184
Shares Held
42.7M
Call Options Held
162K
Put Options Held
102K
View Full List

About PROTHENA CORP PUBLIC LTD CO

PRTA Quotes by TradingView
  • Ticker PRTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,922,800
  • Market Cap $714M
  • Description
  • Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...
More about PRTA
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email